Preliminary Moderna booster data offers hope amid Omicron surge
US biotech Moderna (Nasdaq: MRNA) has announced preliminary neutralizing antibody data against the Omicron variant following the company’s booster candidates at 50µg and 100µg dose levels.
The currently authorized 50µg booster of mRNA-1273, or Spikevax, increased neutralizing antibody levels against Omicron approximately 37-fold compared to pre-boost levels, while a 100µg dose of mRNA-1273 increased neutralizing antibody levels approximately 83-fold compared to pre-boost levels.
"Moderna will continue to rapidly advance an Omicron-specific booster candidate into clinical testing"Stéphane Bancel, chief executive of Moderna, said: “The dramatic increase in COVID-19 cases from the Omicron variant is concerning to all. However, these data showing that the currently authorized Moderna COVID-19 booster can boost neutralizing antibody levels 37-fold higher than pre-boost levels are reassuring.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze